CORRECTION Open Access



Correction: PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway

Xue Gao^{1,2}, Tao Qin¹, Jun Mao^{1,3,4}, Jun Zhang⁵, Shujun Fan¹, Ying Lu^{3,4}, Zhigang Sun², Qingqing Zhang¹, Bo Song¹ and Lianhong Li^{1,3*}

Correction: *J Exp Clin Cancer Res* 38, 256 (2019) https://doi.org/10.1186/s13046-019-1260-6

Following publication of the original article [1], the authors identified an errors in the images of Figs. 3 and 6, specifically:

- Fig. 3E Migration, group of siSCR
- Fig. 6D T47D, group of anti-miR-NC+siPTENP1
- Fig. 6E Migration, group of anti-miR-20a + siSCR

The correct figures are given below.

The correct figures are given be

Published online: 09 August 2023

The original article can be found online at https://doi.org/10.1186/s13046-019-1260-6.

*Correspondence:

Lianhong Li

lilianhong917@sina.com

Reference

 Gao X, Qin T, Mao J, et al. PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway. J Exp Clin Cancer Res. 2019;38:256. https://doi.org/10.1186/ s13046-019-1260-6.



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeccommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

¹ Department of Pathology, Dalian Medical University, 9 Lushunnan Road Xiduan, Dalian 116044, Liaoning Province, China

² Department of Pathology, the First Hospital of Dalian Medical University, Dalian 116027, Liaoning Province, China

³ Key Laboratory of Tumor Stem Cell Research of Liaoning Province, Dalian Medical University, Dalian 116044, Liaoning Province, China

⁴ Teaching Laboratory of Morphology, Dalian Medical University, Dalian 116044, Liaoning Province, China

⁵ Teaching Affairs Department, Dalian Medical University, Dalian 116044, Liaoning Province, China

Gao et al. J Exp Clin Cancer Res (2023) 42:202 Page 2 of 3




Fig. 3 Low PTENP1 level enhances the malignant behavior of BC cells. **a** The viability of transfected BC cells were detected by CCK8 assays at 0, 24, 48,72, 96 h. **b** Knockdown of PTENP1 enhanced the colony formation in BC cells. **c** The proliferation of siPTENP1 transfected cells was increased by Edu staining (Scale bar = $20 \mu m$). **d** Ki67 staining also showed intensive proliferation (Scale bar = $20 \mu m$). **e** The aggressiveness was enhanced with knocking down PTENP1 in MCF-7 cells (Scale bar = $20 \mu m$). **f** The siPTENP1-MCF-7 cells revealed more resistance to ADR. **g** Higher IC₅₀ value was also proved the enhanced chemoresistance to ADR. **h** Weakened colony formation ability was shown in response to ADR. **i** More resistance to ADR was shown in siPTENP1-MCF-7 cells. Low apoptosis rate was detected by flow cytometry. **j** JC-1 staining assay showed altered mitochondrial membrane potential with siPTENP1 transfection. Green fluorescence: the monomer, red fluorescence: the J-aggregates, orange fluorescence: merged photo (Scale bar = $20 \mu m$). **k** TUNEL assay confirmed the incidence of apoptosis (Scale bar = $200 \mu m$). **l** Apoptosis-related molecules expression was determined by western blot. **m** The xenografted tumors were presented with or without ADR treatment. **n** PTEN and Ki67 levels were determined by IHC staining. Data are the means \pm SD of triplicate determinants (*P < 0.05) (Scale bar = $200 \mu m$)

Gao et al. J Exp Clin Cancer Res (2023) 42:202 Page 3 of 3




Fig. 6 Inhibition of miR-20a reverses the promotional effect of siPTENP1 by mediating PTEN expression in BC progression. **a** PTEN mRNA expression was identified with the treatment of miR-20a inhibitor or siPTENP1. **b** PTEN protein level was detected by western blot. **c** The proliferation was measured by CCK8 assays. **d** Colony formation assay was used to measure the colony formation of transfected cells. **e** The aggressiveness was determined by transwell assay (Scale bar = $20 \mu m$). **f** CCK8 assays were carried out to assess the chemoresistance to ADR with different treated BC cells. **g** IC₅₀ values were calculated in differential treated MCF-7 cells. **h** In response to ADR, the colony formation was measured in transfected MCF-7 cells. **i** The AnnexinV and PI staining was used to determine the occurrence of apoptosis. Data are means \pm SD of three independent assays (*P<0.05)